The clinical outcome of first-line necitumumab and FOLFOX regimen was better in CRC patients whose tumors were KRAS-WT compared with those whose tumors harbored KRAS exon 2 mutations (Elez et al., 2016). The gene discussed is KRAS; the disease is colorectal carcinoma.